BioXcel Therapeutics, Inc. BTAIQ
0.04
0.00
0.00%
as of 25 Sep
- Market cap
- $2.3M
- P/E
- 0.0×
Follow BTAIQ
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
78.16% | 74.14% | 76.98% | 63.52% | |
| (145.62%) | (167.91%) | (207.56%) | (259.62%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(996.07%) | 770.98% | 359.26% | 65.40% | |
Average Days of Receivables |
0.00 | 132.47 | 115.94 | 40.34 | |
Free Cash Flow per Share |
(4.10) | (4.72) | (2.43) | (1.68) | |
Free Cash Flow |
(58.21) | (57.61) | (57.38) | (50.90) | |
Piotroski F-Score |
1.00 | 3.00 | 2.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(101.20%) | (134.34%) | (481.14%) | (1,823.21%) | |
Accounts Receivable Turnover |
0.00 | 1.23 | 6.21 | 6.97 | |
Accounts Payable Turnover |
0.06 | 0.01 | 0.03 | 0.02 | |
Inventory Turnover |
0.97 | 0.23 | 0.76 | 0.70 | |
Average Days of Payables |
6,168.99 | 32,718.69 | 13,695.51 | 19,700.56 | |
Days of Inventory on Hand |
173.97 | 1,606.89 | 421.48 | 506.59 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
3,916.36% | 4,711.99% | 4,213.53% | 2,905.66% | |
Selling, General and Administrative Expense of Revenue |
2,763.83% | 3,192.21% | 3,233.24% | 3,176.01% | |
Share Based Compensation of Revenue |
281.65% | 431.00% | 444.41% | 245.82% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.85 | 0.82 | 0.76 | 0.72 | |
Depreciation/Fixed assets |
1.22 | 1.71 | 2.41 | 2.27 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.05 | 0.05 | 0.03 | 0.02 | |
Operating CF per Share |
(4.10) | (4.72) | (2.43) | (1.68) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(9,070.61%) | (10,887.38%) | (11,078.53%) | (9,549.87%) |
Columns are period end dates